PreveCeutical Cannabis and CBD Division
The Cannabis and CBD Division will be responsible for bringing an array of high-quality, medicinal cannabis-based products to market, and overseeing the Company’s nasal delivery Sol-gel research program and the resultant formulations. Through the sale of these products, PreveCeutical aims to help consumers address a number of ailments including chronic pain, epilepsy, anxiety disorders, and more. Products under the Cannabis and CBD Division will vary from transdermal patches and topical creams to capsules and other methods of administering the medicinal cannabis.
According to Statista, the expanding worldwide cannabis market is estimated to be US $63.5 billion by 2024. The Cannabis and CBD Division will further the Company’s aim to become a leader in preventative healthcare by developing and bringing high quality, tailored medicinal cannabis-based products to this expanding global market.
Quote from Stephen
Mr. Stephen Van Deventer, the Company’s Chairman, CEO and President, stated:
“The opening of the Cannabis Division at this crucial moment is very exciting, and continues to move the Company in an important direction. With Canada’s upcoming legalization of recreational cannabis on October 17, 2018, and the reduction of stigma surrounding cannabis products, PreveCeutical sees a potential void in the medicinal cannabis sector as many companies begin to move to recreational market to accommodate demand. This market shift will provide PreveCeutical with the opportunity to focus on the healthcare sector and supply the increasing demand for effective and tailored cannabis-based therapies.” - Chairman, Chief Executive Officer: Stephen Van Deventer